PL3129023T3 - Silne inhibitory rozpuszczalnej hydrolazy epoksydowej - Google Patents
Silne inhibitory rozpuszczalnej hydrolazy epoksydowejInfo
- Publication number
- PL3129023T3 PL3129023T3 PL15768180T PL15768180T PL3129023T3 PL 3129023 T3 PL3129023 T3 PL 3129023T3 PL 15768180 T PL15768180 T PL 15768180T PL 15768180 T PL15768180 T PL 15768180T PL 3129023 T3 PL3129023 T3 PL 3129023T3
- Authority
- PL
- Poland
- Prior art keywords
- epoxide hydrolase
- soluble epoxide
- hydrolase inhibitors
- potent soluble
- potent
- Prior art date
Links
- 229940127514 Epoxide Hydrolase Inhibitors Drugs 0.000 title 1
- 108020002908 Epoxide hydrolase Proteins 0.000 title 1
- 102100025357 Lipid-phosphate phosphatase Human genes 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461971410P | 2014-03-27 | 2014-03-27 | |
| PCT/US2015/023048 WO2015148954A1 (en) | 2014-03-27 | 2015-03-27 | Potent soluble epoxide hydrolase inhibitors |
| EP15768180.0A EP3129023B1 (en) | 2014-03-27 | 2015-03-27 | Potent soluble epoxide hydrolase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3129023T3 true PL3129023T3 (pl) | 2021-08-16 |
Family
ID=54196453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15768180T PL3129023T3 (pl) | 2014-03-27 | 2015-03-27 | Silne inhibitory rozpuszczalnej hydrolazy epoksydowej |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10377744B2 (pl) |
| EP (1) | EP3129023B1 (pl) |
| CN (2) | CN106163521B (pl) |
| AU (1) | AU2015237245B2 (pl) |
| BR (1) | BR112016021641A2 (pl) |
| DK (1) | DK3129023T3 (pl) |
| ES (1) | ES2871027T3 (pl) |
| PL (1) | PL3129023T3 (pl) |
| WO (1) | WO2015148954A1 (pl) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| JP7564888B2 (ja) | 2020-05-01 | 2024-10-09 | ギリアード サイエンシーズ, インコーポレイテッド | Cd73阻害性2,4-ジオキソピリミジン化合物 |
| CN111574432A (zh) * | 2020-06-17 | 2020-08-25 | 安徽省逸欣铭医药科技有限公司 | 一种可溶性环氧水解酶和γ-氨基丁酸双重抑制剂及用途 |
| WO2022093712A1 (en) * | 2020-10-26 | 2022-05-05 | Beth Israel Deaconess Medical Center, Inc. | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY |
| EP4063348A1 (en) | 2021-03-24 | 2022-09-28 | Universitat de Barcelona | Compounds as soluble epoxide hydrolase inhibitors |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| CN113264922A (zh) * | 2021-05-22 | 2021-08-17 | 深圳市术理科技有限公司 | 降解sEH的小分子化合物或其可药用的盐、制备方法及用途 |
| CN113402447B (zh) * | 2021-06-22 | 2022-10-18 | 沈阳药科大学 | 一种sEH抑制剂或其药学上可接受的组合物及其制备方法和应用 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023064370A1 (en) * | 2021-10-13 | 2023-04-20 | Board Of Trustees Of Michigan State University | Soluble epoxide hydrolase inhibitors and use thereof |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20260166021A1 (en) * | 2022-11-02 | 2026-06-18 | Eicosis, Llc | Polymorphic forms of a soluble epoxide hydrolase inhibitor and formulations thereof |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118206542B (zh) * | 2023-03-22 | 2025-06-27 | 沈阳药科大学 | 一种化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用 |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | Kras調節化合物 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| EP4774280A1 (en) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025235691A1 (en) * | 2024-05-08 | 2025-11-13 | Eicosis, Llc | Soluble epoxide hydrolase inhibitors and methods of use therof |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026006549A1 (en) * | 2024-06-26 | 2026-01-02 | Eicosis, Llc | Methods for treating or preventing occular diseases |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN119528936B (zh) * | 2024-11-22 | 2025-10-17 | 深圳安泰维生物医药有限公司 | 一种巴洛沙韦衍生物及其用途 |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5445956A (en) | 1993-08-13 | 1995-08-29 | The Regents Of The University Of California | Recombinant soluble epoxide hydrolase |
| US8815951B2 (en) | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
| BR0314392A (pt) * | 2002-09-16 | 2005-07-12 | Glaxo Group Ltd | Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| WO2006045119A2 (en) | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| CN101535259A (zh) * | 2006-10-20 | 2009-09-16 | 亚瑞特医疗公司 | 作为可溶性环氧化物水解酶抑制剂的苯基脲化合物 |
| CA2666482A1 (en) * | 2006-10-20 | 2008-05-02 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| WO2009062073A1 (en) | 2007-11-08 | 2009-05-14 | Regents Of The University Of California | Alleviating neuropathic pain with eets and seh inhibitors |
| EP2528604B1 (en) * | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| CN104136022A (zh) | 2012-02-01 | 2014-11-05 | 加利福尼亚大学董事会 | 使用seh抑制剂来治疗神经性疼痛 |
| US9034903B2 (en) * | 2012-02-01 | 2015-05-19 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| WO2013138118A1 (en) | 2012-03-14 | 2013-09-19 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
| BR112015000399A2 (pt) * | 2012-07-10 | 2017-06-27 | Ares Trading Sa | derivados de pirazolil pirimidina |
-
2015
- 2015-03-27 BR BR112016021641A patent/BR112016021641A2/pt not_active IP Right Cessation
- 2015-03-27 CN CN201580015513.2A patent/CN106163521B/zh active Active
- 2015-03-27 EP EP15768180.0A patent/EP3129023B1/en active Active
- 2015-03-27 ES ES15768180T patent/ES2871027T3/es active Active
- 2015-03-27 CN CN202110081723.9A patent/CN112898196B/zh active Active
- 2015-03-27 WO PCT/US2015/023048 patent/WO2015148954A1/en not_active Ceased
- 2015-03-27 US US15/128,933 patent/US10377744B2/en active Active
- 2015-03-27 AU AU2015237245A patent/AU2015237245B2/en active Active
- 2015-03-27 PL PL15768180T patent/PL3129023T3/pl unknown
- 2015-03-27 DK DK15768180.0T patent/DK3129023T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3129023B1 (en) | 2021-02-24 |
| CN112898196B (zh) | 2024-12-27 |
| CN106163521A (zh) | 2016-11-23 |
| US20170174665A1 (en) | 2017-06-22 |
| CN106163521B (zh) | 2021-02-09 |
| EP3129023A1 (en) | 2017-02-15 |
| EP3129023A4 (en) | 2017-08-30 |
| BR112016021641A2 (pt) | 2017-08-15 |
| CN112898196A (zh) | 2021-06-04 |
| AU2015237245B2 (en) | 2019-11-28 |
| US10377744B2 (en) | 2019-08-13 |
| DK3129023T3 (da) | 2021-05-25 |
| WO2015148954A1 (en) | 2015-10-01 |
| AU2015237245A1 (en) | 2016-08-25 |
| ES2871027T3 (es) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| IL277299B (en) | Cyclopropylamines as lsd1 inhibitors | |
| IL277167B (en) | Cyclopropylamines as lsd1 inhibitors | |
| EP3129023A4 (en) | Potent soluble epoxide hydrolase inhibitors | |
| IL250642A0 (en) | glycosidase inhibitors | |
| IL252748A0 (en) | Processes for preparing ask1 inhibitors | |
| IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
| IL251420A0 (en) | Triazolopyrazinones as pde1 inhibitors | |
| EP3116503A4 (en) | Hptp-beta inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
| GB201612860D0 (en) | Inhibitors | |
| GB201501004D0 (en) | Inhibitors | |
| IL246718A0 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| EP3186228A4 (en) | Soluble epoxide hydrolase inhibitors and uses thereof | |
| GB201520949D0 (en) | Inhibitors | |
| EP3180003A4 (en) | Pkc-epsilon inhibitors | |
| HK1233944A1 (en) | Potent soluble epoxide hydrolase inhibitors | |
| GB201418154D0 (en) | Inhibitors | |
| HK1239455A1 (zh) | Smyd抑制剂 | |
| AU2014900536A0 (en) | Inhibitors | |
| AU2014900535A0 (en) | Inhibitors |